Iron Overload: all 156 studies

Page 1 of 2. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Native T1 Mapping and ECV in Chronic Hemolytic AnemiaNot yet recruitingNCT07882303
• Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece.Not yet recruitingNCT07352878
• Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.RecruitingNCT07028112
• Early Screening and Treatment of Heart Complication in Sickle Cell DiseaseRecruitingNCT07023666Phase 2
• Neurodegenerative Diseases Progression Markers (MARKERS-NDD)RecruitingNCT06596746
• "Iron Overload and Endocrinological Diseases"RecruitingNCT06137079
• Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron OverloadCompletedNCT03802916Phase 2Results posted
• Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young ChildrenCompletedNCT03591575Phase 4Results posted
• Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional HemosiderosisCompletedNCT03372083Phase 4Results posted
• Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)TerminatedNCT03203850Phase 2Results posted
• Extended Evaluation of Deferasirox Film-coated Tablet (FCT) FormulationCompletedNCT02720536Phase 3Results posted
• Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other AnemiasTerminatedNCT02443545Phase 4Results posted
• Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron OverloadCompletedNCT02435212Phase 2Results posted
• Non-invasive Quantification of Liver Iron With MRICompletedNCT02425956Not applicableResults posted
• Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)CompletedNCT02125877Phase 2Results posted
• Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other AnemiasTerminatedNCT02041299Phase 4Results posted
• Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell DiseaseCompletedNCT01835496Phase 1Results posted
• An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)CompletedNCT01736540Phase 4Results posted
• Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)TerminatedNCT01671111Phase 2Results posted
• Post Hematopoietic Stem Cell TransplantationCompletedNCT01610297Phase 4Results posted
• Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation TherapyTerminatedNCT01604941Phase 2Results posted
• Massive Iron Deposit AssessmentCompletedNCT01572922Not applicableResults posted
• Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron OverloadTerminatedNCT01459718Phase 2Results posted
• Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron OverloadTerminatedNCT01363908Phase 2Results posted
• Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron OverloadCompletedNCT01254227Phase 2Results posted
• Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron OverloadCompletedNCT01186419Phase 2Results posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension StudyCompletedNCT01033747Phase 2/3Results posted
• Clinical Importance of Treating Iron Overload in Sickle Cell DiseaseTerminatedNCT00981370Phase 3Results posted
• Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron OverloadCompletedNCT00901199Phase 2Results posted
• Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension StudyCompletedNCT00873041Phase 2Results posted
• Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to FoodCompletedNCT00845871Phase 4Results posted
• Deferoxamine for Iron Overload Before Allogeneic Stem Cell TransplantationTerminatedNCT00658411Not applicableResults posted
• Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional HemosiderosisCompletedNCT00631163Phase 2Results posted
• Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell TransplantTerminatedNCT00602446Phase 2Results posted
• Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron OverloadCompletedNCT00600938Phase 2Results posted
• Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric PatientsCompletedNCT00529152Phase 3Results posted
• Cardiac T2* in Beta-thalassemia Patients on Deferasirox TreatmentCompletedNCT00447694Phase 2Results posted
• Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary HemochromatosisCompletedNCT00395629Phase 1/2Results posted
• A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.CompletedNCT00390858Phase 2Results posted
• Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia PatientsCompletedNCT00303329Phase 2Results posted
• Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)CompletedNCT00171301Phase 4Results posted
• An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron OverloadCompletedNCT00171210Phase 3Results posted
• Study for the Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00117507Phase 4Results posted
• Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease PatientsCompletedNCT00110617Phase 2Results posted
• Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00110266Phase 2Results posted
• Evaluate the Efficacy and Safety of Irochel for the Management of Iron Overload in Thalassemia Patients in Comparison With DeferoxamineCompletedNCT07782931Phase 3
• Iron Accumulation in Erythrocytes in PatientsCompletedNCT07486531
• Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary HemochromatosisActive, not recruitingNCT07332091Phase 2
• Elastography vs Iron Regulators in the Diagnosis of Hepatic Fibrosis- Iron Overload in Children With Beta- ThalassemiaCompletedNCT07153926
• Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy AdultsCompletedNCT06726863Phase 1
• Association Between Iron Reserves and Perioperative Neurocognitive DisordersCompletedNCT06502912
• Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron OverloadCompletedNCT06468423Not applicable
• Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational MaterialsCompletedNCT06215287
• Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron AbsorptionActive, not recruitingNCT06146608
• Study to Assess Iron Chelation Therapy in Patients With Chronic Iron OverloadCompletedNCT05440487
• Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded PatientsCompletedNCT05355766Phase 2
• Inhibitory Effect of a Polyphenol Supplement on Dietary Iron Absorption in Adults with ThalassemiaCompletedNCT05326503Not applicable
• Fully Automated High-Throughput Quantitative MRI of the LiverCompletedNCT05294471
• MRI T2* Mapping of Myocardium, Liver, Pancreas and Pituitary GlandStatus unknownNCT04835285Not applicable
• Safety of SP-420 in the Treatment of Transfusional Iron OverloadTerminatedNCT04741542Phase 1
• MRI QSM Imaging for Iron OverloadCompletedNCT04631718
• Long-term Clinical Study of CN128 in Thalassemia PatientsCompletedNCT04614779Phase 2
• Natural History Study of FDXR Mutation-related MitochondriopathyCompletedNCT04580979
• Endocrine Function During Deferasirox TherapyCompletedNCT04515680
• Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCTCompletedNCT04423237
• Platelet Changes in Cases of Iron Overload(IO)Status unknownNCT04329377
• Platelet Changes in Cases of Chronic Iron Over LoadStatus unknownNCT04329286
• Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major ThalassemiaCompletedNCT04292314Phase 2/3
• Ethnic Differences in Iron Absorption (FeGenes)Active, not recruitingNCT04198545
• Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating TherapyCompletedNCT04171635
• Iron Supplementation and Side EffectsCompletedNCT04018300Not applicable
• Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol SupplementCompletedNCT03990181Not applicable
• A Prospective, Mono-center, Interventional Study Evaluating the Effect of One Year Initial Care by Hygieno-dietary Advices With or Without Phlebotomy on Glycemia After at Least 5 Years in Patients With Dysmetabolic Iron Overload SyndromeCompletedNCT03942432Not applicable
• SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare AnemiasWithdrawnNCT03801889Phase 2
• Validation of a Point-of-care Device Measuring Ferritin With Capillary BloodWithdrawnNCT03800446Not applicable
• The Iron Content of Ferritin in Serum and Urine of Children With High Serum Ferritin LevelsTerminatedNCT03777904
• Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology GroupWithdrawnNCT03141398
• The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia MajorStatus unknownNCT02984475Phase 4
• Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesCompletedNCT02880033Not applicable
• Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron OverloadStatus unknownNCT02833493
• Evaluation of Myocardial Iron Deposition in Patients of Heart Failure Using T2* MR ImagingCompletedNCT02527330
• Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia PatientsStatus unknownNCT02474420Not applicable
• Reproductive Capacity and Iron Burden in ThalassemiaCompletedNCT02308904Not applicable
• Evaluation of Body Iron Stores in Overweight Healthy VolunteersCompletedNCT02304874Not applicable
• Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-ThalassemiaTerminatedNCT02274233Phase 1
• Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) PatientsCompletedNCT02164253Phase 2
• Iron Homoeostasis in InflammationCompletedNCT02155114
• Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron ContentCompletedNCT02025543
• Transfusional Iron Overload Among Leukemia SurvivorsCompletedNCT01965171
• Treatment of Iron Overload Requiring Chelation TherapyWithdrawnNCT01927913Phase 2
• Renal Function Among Thalassemia Patients Treated by a Oral Chelator DeferasiroxCompletedNCT01905774
• Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic SyndromeWithdrawnNCT01892644Phase 2
• Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox TherapyCompletedNCT01874405
• Active Drug Surveillance Program of Ferriprox UseCompletedNCT01838291
• Apotransferrin in AtransferrinemiaActive, not recruitingNCT01797055Phase 2
• Zinc and Diabetes in Patients With Thalassemia: a Pilot StudyCompletedNCT01772680Not applicable
• Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload PatientsCompletedNCT01572818Not applicable
• Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary StudyCompletedNCT01556360
• Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic AnemiaCompletedNCT01546415Phase 4

← Iron Overload overview